Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TBPH | US
0.15
0.92%
Healthcare
Biotechnology
30/06/2024
24/04/2026
16.46
16.26
16.50
16.14
Theravance Biopharma Inc. a biopharmaceutical company discovers develops and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI a once-daily nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program as well as Viatris Inc. Theravance Biopharma Inc. was incorporated in 2013 and is based in George Town the Cayman Islands.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
24.1%1 month
31.7%3 months
62.6%6 months
60.7%-
9.91
2.18
0.24
0.13
-9.69
6.00
-0.05
-39.17M
805.26M
805.26M
-
-89.46
-
3.70
-19.27
24.09
20.90
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.10
Range1M
2.54
Range3M
7.75
Rel. volume
0.60
Price X volume
4.43M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| uniQure N.V | QURE | Biotechnology | 18.03 | 878.02M | 2.79% | n/a | 550.36% |
| KalVista Pharmaceuticals Inc | KALV | Biotechnology | 19.63 | 848.32M | 2.88% | n/a | 3.62% |
| Savara Inc | SVRA | Biotechnology | 5.12 | 842.76M | 3.64% | n/a | 26.18% |
| SPRY | SPRY | Biotechnology | 8.29 | 803.65M | -0.12% | n/a | 0.07% |
| Sensei Biotherapeutics Inc | SNSE | Biotechnology | 31.79 | 799.55M | -2.54% | n/a | 9.67% |
| PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 11.7 | 798.99M | -3.78% | n/a | -216.56% |
| Arbutus Biopharma Corporation | ABUS | Biotechnology | 4.2 | 792.88M | -1.18% | n/a | 6.09% |
| Omeros Corporation | OMER | Biotechnology | 13.53 | 784.02M | 0.07% | n/a | -356.63% |
| Janux Therapeutics Inc. Common Stock | JANX | Biotechnology | 15.01 | 782.99M | -1.18% | n/a | 3.62% |
| MannKind Corporation | MNKD | Biotechnology | 2.7 | 742.49M | -0.37% | 132.00 | -149.80% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.44 | 790.55M | 1.30% | 11.62 | 116.21% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 17.7 | 737.79M | 2.31% | 42.05 | 64.69% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.01 | 694.62M | -0.17% | 65.18 | 77.00% |
| Ennis Inc | EBF | Building Products & Equipment | 20.33 | 528.66M | -1.26% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.1 | 521.76M | -0.91% | n/a | 1.50% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 23.53 | 390.77M | -0.88% | 34.27 | 26.82% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 7.48 | 337.57M | 8.41% | n/a | 3644.76% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.31 | 317.09M | 1.85% | n/a | 174.23% |
| Marine Products Corporation | MPX | Recreational Vehicles | 7.99 | 277.39M | -0.99% | 13.23 | 0.00% |
| Urban One Inc | UONEK | Broadcasting - Radio | 4.9543 | 262.62M | -0.42% | n/a | 268.43% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -9.69 | 0.53 | Cheaper |
| Ent. to Revenue | 6.00 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.18 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 62.60 | 72.80 | Par |
| Debt to Equity | 0.24 | -1.23 | Expensive |
| Debt to Assets | 0.13 | 0.25 | Cheaper |
| Market Cap | 805.26M | 3.66B | Emerging |